The market for pre-filled syringes is growing rapidly and is expected to reach $12.8 billion by 2027, marking a $7.0 billion increase from 2020. As high demand from biologics and their successive biosimilars stimulates innovation in the space, pharmaceutical manufacturers must stay abreast of the latest trends to remain competitive.
Beyond the interest driven by biologics, the ubiquitous benefits offered by pre-filled syringes are spurring further demand in the market. Single use devices not only offer an inherent safety advantage, but can also lead to lower manufacturing and labor costs. The increased accuracy and precision in dosing reduces costs for pharmaceutical manufacturers and protects the user during self-injection.
However, there are a number of challenges for manufacturers in the pre-filled syringe market. These syringes are typically manufactured in an aseptic, or sterile, environment where all components, processes, and personnel must be validated as safe for use. The necessary cleaning and sterilization, as well as the enhanced environmental monitoring for the fill finish stage, results in a complex manufacturing process entailing rigorous quality control measures, specialized equipment, and extensive validation to guarantee a safe product. It is crucial to work with partners who have experience in the industry and can provide guidance throughout the process. Learn more about the benefits for consumers, providers, and manufacturers, and the importance of partnering with a reliable fill finish facility.